TAJ-β inhibitors represent a specialized class of chemical compounds designed to specifically inhibit the function of the TAJ-β protein, a molecule known to play a role in various cellular regulatory pathways. TAJ-β inhibitors operate by binding to the active sites or key functional domains of the TAJ-β protein, thus preventing its normal activity within the cell. These inhibitors are often developed to fit the precise structural features of the TAJ-β protein, ensuring that they can effectively block its interactions or catalytic actions. The inhibitors may target different regions of the protein, such as its binding pockets or allosteric sites, depending on their mode of action and the specific mechanism by which they interfere with the protein's function. The chemical design of TAJ-β inhibitors is crucial for achieving a high degree of specificity, ensuring they interact with TAJ-β while minimizing interaction with other proteins.
TAJ-β inhibitors are synthesized using advanced organic synthesis techniques that allow the precise assembly of molecules with defined structural features. These compounds often feature a combination of hydrophobic and hydrophilic regions that are designed to complement the three-dimensional shape of the TAJ-β protein. Some inhibitors may include functional groups capable of forming strong covalent or non-covalent bonds with the protein's active sites, thereby enhancing their inhibitory potency. The solubility, stability, and reactivity of these inhibitors are carefully considered during their design, as these properties influence how effectively the inhibitor can interact with TAJ-β under different conditions. The diversity in the structural composition of TAJ-β inhibitors allows for the fine-tuning of their binding affinities, making them a valuable class of compounds for studying the biochemical functions and regulatory mechanisms associated with the TAJ-β protein.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
Inhibits p38 MAPK, potentially affecting inflammatory response pathways TAJ-β might be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, could disrupt signaling pathways important for cell survival and proliferation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, might influence stress response pathways and apoptosis related to TAJ-β activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor, potentially affecting the MAPK/ERK pathway, which could be relevant to TAJ-β's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, could further impact signaling pathways TAJ-β is hypothesized to participate in. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor, might modulate cellular growth and autophagy processes associated with TAJ-β. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor, could affect cell growth and differentiation pathways involving TAJ-β. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Pan-caspase inhibitor, potentially influencing apoptosis pathways that TAJ-β might regulate. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, could impact protein degradation pathways relevant to TAJ-β's function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates NF-κB and other signaling molecules, potentially affecting inflammation and cell growth. | ||||||